Getinge (GETI-B.ST) Stock Analysis & AI Equity Report

Medical - Devices SEK Explore free reports

Getinge (GETI-B.ST) overview

Getinge (GETI-B.ST) stock analysis and AI equity research. For the latest completed financial year, 2024, Getinge reported revenue of SEK 34,759m and operating profit of SEK 2,854m; the year-end share price was 181.55 SEK and market capitalisation was SEK 49,449m. Getinge is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Getinge's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueSEK 33,005mFY 2024
Share price181.55 SEKFY 2024 year end
RevenueSEK 34,759mFY 2024
Operating profitSEK 2,854mFY 2024
Net earningsSEK 1,655mFY 2024
Market capitalisationSEK 49,449mFY 2024 year end

Figures updated on 2026-07-18. Data will be refreshed during report generation.

About Getinge

Getinge develops and sells equipment, systems and services for hospitals and life science institutions, with offerings across intensive care, cardiovascular procedures, operating rooms, sterile reprocessing and life science. Its portfolio includes ventilators, anesthesia and operating room equipment, sterilization systems, and digital workflow solutions designed to improve clinical results and hospital efficiency.

Generate the Getinge report

Getinge is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, typically within about 30 minutes

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Getinge and represent the latest completed financial year (2024). See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.